Trial reportBrain : a journal of neurology2015
Improving response inhibition systems in frontotemporal dementia with citalopram.
Trial report in Brain : a journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Psychotherapy and inhibitory control: Insights from fMRI research.Psychiatry and clinical neurosciences · 2026Pooled it
- Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.Human brain mapping · 2016Trial
- Magnetoencephalography in human neuroscience research: planning, piloting, implementation and quality assurance.Nature protocols · 2026Review
- Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Interpretable multimodal learning for integrating neuroimaging and genetic data in Alzheimer's disease.Frontiers in radiology · 2026Article
- Examining neuropsychiatric symptoms and functional decline in behavioral variant frontotemporal dementia.International review of psychiatry (Abingdon, England) · 2025Article
- Revisiting the Role of Serotonin in Attention-Deficit Hyperactivity Disorder: New Insights from Preclinical and Clinical Studies.Clinical drug investigation · 2025Review
- Article
- Interaction of metabolic and inflammatory dysregulation on central degeneration and cognitive function in behavioral variant Frontotemporal dementia.Journal of neurology · 2025Article
- GABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Antidepressant use and cognitive decline in patients with dementia: a national cohort study.BMC medicine · 2025Article
- A neuroanatomical and cognitive model of impaired social behaviour in frontotemporal dementia.Brain : a journal of neurology · 2024Review
- Cognitive control subprocess deficits and compensatory modulation mechanisms in patients with frontal lobe injury revealed by EEG markers: a basic study to guide brain stimulation.General psychiatry · 2023Article
- Multidimensional inhibitory signatures of sentential negation in behavioral variant frontotemporal dementia.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
- New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol.BMJ open · 2022Article
- The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration.Translational psychiatry · 2022Article
- Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation of Inhibitory Control in Older Adults.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches.Molecular psychiatry · 2022Review
- The Role of Oxytocin in Social Circuits and Social Behavior in Dementia.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy.Movement disorders clinical practice · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Disinhibition is a cardinal feature of the behavioural variant of frontotemporal dementia, presenting as impulsive and impetuous behaviours that are often difficult to manage. The options for symptomatic treatments are limited, but a potential target for therapy is the restoration of serotonergic function, which is both deficient in behavioural variant frontotemporal dementia and closely associated with inhibitory control. Based on preclinical studies and psychopharmacological interventions in other disorders, we predicted that inhibition would be associated with the right inferior frontal gyrus and dependent on serotonin. Using magnetoencephalography and electroencephalography of a Go-NoGo paradigm, we investigated the neural basis of behavioural disinhibition in behavioural variant frontotemporal dementia and the effect of selective serotonin reuptake inhibition on the neural systems for response inhibition. In a randomized double-blinded placebo-controlled crossover design study, 12 patients received either a single 30 mg dose of citalopram or placebo. Twenty age-matched healthy controls underwent the same magnetoencephalography/electroencephalography protocol on one session without citalopram, providing normative data for this task. In the control group, successful NoGo trials evoked two established indices of successful response inhibition: the NoGo-N2 and NoGo-P3. Both of these components were significantly attenuated by behavioural variant frontotemporal dementia. Cortical sources associated with successful inhibition in control subjects were identified in the right inferior frontal gyrus and anterior temporal lobe, which have been strongly associated with behavioural inhibition in imaging and lesion studies. These sources were impaired by behavioural variant frontotemporal dementia. Critically, citalopram enhanced the NoGo-P3 signal in patients, relative to placebo treatment, and increased the evoked response in the right inferior frontal gyrus. Voxel-based morphometry confirmed significant atrophy of inferior frontal gyrus, alongside insular, orbitofrontal and temporal cortex in our patient cohort. Together, these data suggest that the dysfunctional prefrontal cortical systems underlying response inhibition deficits in behavioural variant frontotemporal dementia can be partially restored by increasing serotonergic neurotransmission. The results support a translational neuroscience approach to impulsive neurological disorders and indicate the potential for symptomatic treatment of behavioural variant frontotemporal dementia including serotonergic strategies to improve disinhibition.media-1vid110.1093/brain/awv133_video_abstractawv133_video_abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.